CLINICAL TRIALS PROFILE FOR ELACESTRANT DIHYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for elacestrant dihydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02338349 ↗ | A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer | Completed | Radius Health, Inc. | Phase 1 | 2015-01-01 | The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of elacestrant (RAD1901) in patients with advanced ER+, HER2-negative breast cancer. |
| NCT02338349 ↗ | A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer | Completed | Radius Pharmaceuticals, Inc. | Phase 1 | 2015-01-01 | The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of elacestrant (RAD1901) in patients with advanced ER+, HER2-negative breast cancer. |
| NCT02650817 ↗ | Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer | Completed | Radius Health, Inc. | Phase 1 | 2016-04-01 | The purpose of this study is to visualize and quantify ER-binding sites during treatment with Elacestrant (RAD1901) |
| NCT02650817 ↗ | Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer | Completed | Radius Pharmaceuticals, Inc. | Phase 1 | 2016-04-01 | The purpose of this study is to visualize and quantify ER-binding sites during treatment with Elacestrant (RAD1901) |
| NCT02653417 ↗ | Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms | Terminated | Radius Health, Inc. | Phase 2 | 2015-12-01 | The primary objective of this study was to determine the clinical safety of RAD1901 and to evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor symptoms (VMS; "hot flashes") in postmenopausal women. |
| NCT02653417 ↗ | Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms | Terminated | Radius Pharmaceuticals, Inc. | Phase 2 | 2015-12-01 | The primary objective of this study was to determine the clinical safety of RAD1901 and to evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor symptoms (VMS; "hot flashes") in postmenopausal women. |
| NCT03778931 ↗ | Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer | Active, not recruiting | Radius Pharmaceuticals, Inc. | Phase 3 | 2019-05-10 | This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI) . |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for elacestrant dihydrochloride
Condition Name
Clinical Trial Locations for elacestrant dihydrochloride
Trials by Country
Clinical Trial Progress for elacestrant dihydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for elacestrant dihydrochloride
Sponsor Name
